| CASE REPORT |
|
| Year : 2022 | Volume
: 2
| Issue : 3 | Page : 649-651 |
|
|
Netarsudil-associated reticular epithelial edema in a corneal ulcer
Arjun Velayudhan Nair, Devi Rosette, Revathi Rajaraman
Department of Cornea and Refractive Services, Aravind Eye Hospital and Post-Graduate Institute of Ophthalmology, Coimbatore, Tamil Nadu, India
Correspondence Address:
Dr. Arjun Velayudhan Nair
Department of Cornea and Refractive Services, Aravind Eye Hospital and Post-Graduate Institute of Ophthalmology, Coimbatore, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/ijo.IJO_2417_21
|
|
|
Netarsudil is a novel Rho-kinase (ROCK) inhibitor approved for the reduction in intraocular pressure (IOP). Reticular epithelial edema (REE) is a side effect commonly noted in patients on netarsudil with pre-existing corneal edema. We report a case of netarsudil-associated REE in a corneal ulcer with secondary glaucoma. The patient had a recurrence of REE even after debridement, and the resolution was seen only after discontinuing the drug. Netarsudil-associated REE is a side effect previously reported in patients with corneal edema and decompensation. To the best of our knowledge, there are no previous case reports of REE in a corneal ulcer. ROCK inhibitors have additional anti-inflammatory and antifibrotic action, which can lead to delayed healing and scarring in corneal ulcers. In conclusion, ROCK inhibitors should be used judiciously in corneal ulcers.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
